The unitary patent and Unified Patent Court will have wide-ranging implications for life sciences companies. In the first of what will be a regular column on the topics by law firm Taylor Wessing, Paul England explores current developments on issues such as costs and judges.
Not many years ago, the conventional wisdom was that the Court of Justice of the European Union (CJEU) would usually follow the opinion of its Advocate General (AG) on any question before it, but that it could not be guaranteed to do so.
More recently, and although it is still a minority, the proportion of cases in which the CJEU has not followed the AG has increased. What does this mean for the challenges by Spain to the legislation implementing and governing the unitary patent and its translation arrangements?
The Spanish government’s two challenges to the patent were filed before the CJEU on May 31, 2013. It sought a declaration that the Unitary Patent Regulation which provides for the patent is legally non-existent or should otherwise be annulled, and a request that the ‘Translation Regulation’, providing rules for the patent’s language, is annulled in whole or in part. In other words, the action is intended to stop the unitary patent in its tracks.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CJEU, patent, UPC, unitary patent, Taylor Wessing